Yixintang Pharmaceutical Group (002727) Fair Value & Analysis
Healthcare · CN · Market cap 6.4B CNY
Analysis
Yixintang Pharmaceutical Group (002727) currently trades at ¥10.62, while our model-based Fair Value estimate is ¥18.92 — implying the stock looks roughly 78.2% undervalued today. We read business quality at 94/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
Yixintang Pharmaceutical Group Co., Ltd., together with its subsidiary, engages in the pharmaceutical retail chain and pharmaceutical distribution business. The company is involved in the wholesale, retail, leasing, and operation of medical devices; sale of food, disinfectants, disinfection equipment, sanitary products and disposable medical products, household appliances, adult toys, agricultural and sideline products, cosmetics, and daily sundries and necessities; manufacturing of glasses; provision of value-added telecommunications, Internet live broadcast technology, and Internet information services for medicines, as well as clinic and foot bath services; operation of aquatic wild animals and call center; retail of publications; and decoction services for Chinese herbal medicines. It also engages in the agency sale of single-purpose commercial prepaid cards and China sports lottery; and maternal and child care activities. In addition, the company provides health care, housekeep…
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.